scispace - formally typeset
R

Rafael López-Rojas

Researcher at University of Seville

Publications -  34
Citations -  2538

Rafael López-Rojas is an academic researcher from University of Seville. The author has contributed to research in topics: Acinetobacter baumannii & Colistin. The author has an hindex of 20, co-authored 34 publications receiving 2136 citations. Previous affiliations of Rafael López-Rojas include Carlos III Health Institute & Spanish National Research Council.

Papers
More filters
Journal ArticleDOI

ARG-ANNOT, a New Bioinformatic Tool To Discover Antibiotic Resistance Genes in Bacterial Genomes

Sushim K. Gupta, +6 more
- 01 Jan 2014 - 
TL;DR: A concise database for BLAST using a Bio-Edit interface that can detect AR genetic determinants in bacterial genomes and can rapidly and easily discover putative new AR geneticeterminants is created.
Journal ArticleDOI

Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice.

Jennifer A. Gaddy, +5 more
- 01 Mar 2012 - 
TL;DR: It is demonstrated that the virulence of the ATCC 19606T strain depends on the expression of a fully active acinetobactin-mediated system, and Interestingly, the three models also showed that impairment of BasD production results in an intermediate virulence phenotype compared to those of the parental strain and the BauA mutant.
Journal ArticleDOI

Impaired Virulence and In Vivo Fitness of Colistin-Resistant Acinetobacter baumannii

Rafael López-Rojas, +7 more
- 15 Feb 2011 - 
TL;DR: The colistin-resistant strain has lower affinity for Colistin, reduced in vivo fitness, and decreased virulence, both in terms of mortality and survival in a mouse model of peritoneal sepsis, which may explain the low incidence and dissemination of colistIn resistance in A. baumannii in clinical settings.
Journal ArticleDOI

Vaccination with Outer Membrane Complexes Elicits Rapid Protective Immunity to Multidrug-Resistant Acinetobacter baumannii

Michael J. McConnell, +5 more
- 01 Jan 2011 - 
TL;DR: Results indicate that prophylactic vaccination and antibody-based therapies based on an outer membrane complex vaccine may be viable approaches to preventing the morbidity and mortality caused by A. baumannii.
Journal ArticleDOI

Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii

María Eugenia Pachón-Ibáñez, +8 more
- 01 Mar 2010 - 
TL;DR: Rifampin in monotherapy or with imipenem, sulbactam, or colistin showed efficacy against MDR A. baumannii in experimental models of pneumonia and meningitis.